Search

Your search keyword '"Fernandes, Peter"' showing total 5 results
Start Over Author "Fernandes, Peter" Journal pulmonary circulation
5 results on '"Fernandes, Peter"'

1. Pulmonary hypertension in interstitial lung disease: Clinical trial design and endpoints: A consensus statement from the Pulmonary Vascular Research Institute's Innovative Drug Development Initiative—Group 3 Pulmonary Hypertension

Author

Nathan, Steven D., primary, Fernandes, Peter, additional, Psotka, Mitchell, additional, Vitulo, Patrizio, additional, Piccari, Lucilla, additional, Antoniou, Katerina, additional, Nikkho, Sylvia M., additional, and Stockbridge, Norman, additional

Published
2022
Full Text
View/download PDF

2. Clinical significance of pulmonary hypertension in interstitial lung disease: A consensus statement from the Pulmonary Vascular Research Institute's innovative drug development initiative—Group 3 pulmonary hypertension

Author

Nikkho, Sylvia M., primary, Richter, Manuel J., additional, Shen, Eric, additional, Abman, Steven H., additional, Antoniou, Katerina, additional, Chung, Jonathan, additional, Fernandes, Peter, additional, Hassoun, Paul, additional, Lazarus, Howard M., additional, Olschewski, Horst, additional, Piccari, Lucilla, additional, Psotka, Mitchell, additional, Saggar, Rajan, additional, Shlobin, Oksana A., additional, Stockbridge, Norman, additional, Vitulo, Patrizio, additional, Vizza, Carmine Dario, additional, Wort, Stephen J., additional, and Nathan, Steven D., additional

Published
2022
Full Text
View/download PDF

3. Pulmonary hypertension in interstitial lung disease: Clinical trial design and endpoints:Aconsensus statement from the Pulmonary Vascular Research Institute's Innovative Drug Development Initiative--Group 3 Pulmonary Hypertension.

Author

Nathan, Steven D., Fernandes, Peter, Psotka, Mitchell, Vitulo, Patrizio, Piccar, Lucilla, Antoniou, Katerina, Nikkho, Sylvia M., and Stockbridge, Norman

Subjects
*PULMONARY hypertension, *EXPERIMENTAL design, *DRUG development, *RESEARCH institutes, *INTERSTITIAL lung diseases, *LUNG diseases
Abstract

Pulmonary hypertension (PH) associated with interstitial lung disease (ILD) is an attractive target for clinical trials of PH medications. There are many factors that need to be considered to prime such studies for success. The patient phenotype most likely to respond to the intervention requires weighing the extent of the parenchymal lung disease against the severity of the hemodynamic impairment. The inclusion criteria should not be too restrictive, thus enabling recruitment. The trial should be of sufficient duration to meet the chosen endpoint which should reflect how the patient feels, functions, or survives. This paper summarizes prior studies in PH-ILD and provides a framework of the type of studies to be considered. Inclusion criteria, clinical trial endpoints, and pharmacovigilance in the context of PH-ILD trials are also addressed. Through lessons learnt from prior studies, suggestions and guidance for future clinical trials in PH-ILD are also provided. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results